News &amp; Updates

Individuals with type 1 diabetes (T1D) may experience mild, temporary glycaemic elevations following receipt of a COVID-19 booster vaccine, according to a study.

COVID-19 booster may cause transient glycaemic elevations in T1D

Original New Drug Application Approvals by US FDA (01-15 September 2023)

New drug applications approved by US FDA as of 01-15 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 September 2023)

Mpox vax holds up against severe infection

14 Sep 2023 by

Individuals who have received mpox vaccination or have been previously exposed to mpox infection, which is used to be called monkeypox, appear to be better protected against severe disease from a subsequent infection, as shown in a study.

Mpox vax holds up against severe infection

Oral antipsychotics show similar safety profile in older adults after major surgery

Comparisons of atypical antipsychotics and haloperidol reveal similar rates of in-hospital adverse clinical events in older patients with postoperative delirium who have taken an oral low-to-moderate dose antipsychotic drug, a study has shown.

Oral antipsychotics show similar safety profile in older adults after major surgery

Treating iron deficiency in heart failure provides some benefits

Use of ferric carboxymaltose in patients who have heart failure with a reduced ejection fraction and iron deficiency appears to yield only numerical improvements the hierarchical composite of death, hospitalizations for heart failure, or 6-minute walk distance as compared with placebo, according to data from the HEART-FID trial.

Treating iron deficiency in heart failure provides some benefits

Is it safe to take olmesartan in combination therapy for advanced hypertension?

14 Sep 2023 by

Use of olmesartan in combination practice is safe and results in similar cardiovascular composite outcomes, including myocardial infarction (MI), when compared with active comparators in hypertensive patients who need more than two antihypertensive medications, reports a study.

Is it safe to take olmesartan in combination therapy for advanced hypertension?

14 Sep 2023

Bulevirtide boasts high barrier to resistance for chronic hepatitis delta

A recent study has found no amino acid substitutions associated with reduced sensitivity to bulevirtide (BLV) monotherapy, a hepatitis D/B virus (HDV/HBV) entry inhibitor, at baseline or week 24 in patients with virologic breakthrough after BLV treatment.

Bulevirtide boasts high barrier to resistance for chronic hepatitis delta

13 Sep 2023

When is the best time to take antihypertensives?

It remains uncertain whether morning or bedtime dosing of antihypertensive drugs is better than the other in terms of efficacy, but the latter appears to significantly reduce the incidence of myocardial infarction (MI), suggests a study.

When is the best time to take antihypertensives?

Divarasib yields durable response across KRAS G12C-positive tumours

The covalent KRAS G12C inhibitor divarasib shows durable antitumour activity in patients harbouring KRAS G12C-positive tumours, with mostly low-grade adverse events, as shown in the phase I GO42144 study.

Divarasib yields durable response across KRAS G12C-positive tumours